7 April 2022 - Approval validates the use of novel pathway for bioequivalence of complex generic drug products, which increases access to affordable versions of life saving drugs.

Clayton Pharmaceuticals announces that they have received FDA approval for sucralfate oral suspension with competitive generic therapy designation.

Read Clayton Pharmaceuticals press release